Derek L. Buhl

机构：AbbVie (United States), Precision for Medicine (United States), Takeda (United States), Takeda (Japan) · ORCID：0000-0003-4433-7150

发表论文 68 篇 · 总被引 5550 次 · h-index 23

代表论文

• The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial (2023 · Neuropsychopharmacology · 被引 72)
• Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers (2023 · Schizophrenia Research · 被引 26)
• Identifying time‐resolved features of nocturnal sleep characteristics of narcolepsy using machine learning (2024 · Journal of Sleep Research · 被引 15)
• High-order brain interactions in ketamine during rest and task: a double-blinded cross-over design using portable EEG on male participants (2024 · Translational Psychiatry · 被引 14)
• A personalized earbud for non-invasive long-term EEG monitoring (2024 · Journal of Neural Engineering · 被引 12)
• Novel biomarkers derived from the Maintenance of Wakefulness Test as predictors of sleepiness and response to treatment (2024 · SLEEP · 被引 11)